OSE IMMUNOTHERAPEUTICS |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.56 EUR | -0.71% |
|
+3.35% | +29.91% |
| Apr. 17 | OSE: licensing agreement with AbbVie enters into force | CF |
| Apr. 17 | OSE Immunotherapeutics Finalizes Drug License, Collaboration Deal With AbbVie | MT |
Presenter SpeechUnknown Executive (Executives)Welcome to OSE webinar. We are very happy today ...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
OSE Immunotherapeutics develops first-in-class assets in immuno-oncology (IO) & immuno-inflammation (I&I). The Company's current well-balanced first-in-class clinical pipeline includes:
- Tedopi® (lung cancer vaccine): positive Phase 3 results in NSCLC. Other Phase 2 trials of Tedopi® in combination are ongoing in solid tumors;
- OSE-279 (anti-PD1): Phase 1/2 positive results in solid tumors;
- OSE-127/Lusvertikimab (humanized monoclonal antibody antagonist of IL-7 receptor): Phase 2 in Ulcerative Colitis. Preclinical research in leukemia;
- FR-104/VEL-101 (anti-CD28 mAb): partnership with Veloxis in transplantation; Phase 1/2 in renal transplant (CHU Nantes);
- BI 765063/BI 770371 (anti-SIRP? mAb): partnership with Boehringer Ingelheim in advanced solid tumors;
- OSE-230 (ChemR23 agonist mAb): partnership with AbbVie in chronic inflammation.
OSE Immunotherapeutics expects to generate further significant value from its three proprietary drug discovery platforms:
- Pro-resolutive mAb platform focused on targeting and advancing inflammation resolution in I&I;
- Myeloid Checkpoint platform focused on optimizing the therapeutic potential of myeloid cells in IO;
- Cytokine platform focused on leveraging the Cis-Delivery of cytokine in IO and I&I.
Calendar
2024-06-05
- Spring European Midcap Event
Trading Rating
Investor Rating
ESG Refinitiv
D
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
5.56
EUR
Average target price
7.15
EUR
Spread / Average Target
+28.60%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +29.91% | 128M | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- OSE Stock
- News OSE Immunotherapeutics
- Transcript : OSE Immunotherapeutics SA - Special Call
